603456 Zhejiang Jiuzhou Pharmaceutical
- 16.36
- -0.24-1.45%
Zhejiang Jiuzhou Pharmaceutical News
Jiuzhou Pharmaceutical (603456.SH): In July 2023, the company was elected as the Deputy Director of Zhejiang Synthetic Biology Industry Technology Alliance
Gelonghui, May 8, 丨 Jiuzhou Pharmaceutical (603456.SH) said on the investor interactive platform that with years of new drug research and technology, the company already has many R&D technology platforms such as catalysis, peptides, and conjugation. In July 2023, the company was elected as the deputy director unit of the Zhejiang Synthetic Biotechnology Industry Technology Alliance. The company's R&D team focuses on developing high-performance enzymes and high-efficiency enzyme catalytic processes, and has made good progress in the biogreen manufacturing of small-molecule drugs, such as in the development of tins, significantly reducing costs and improving product market competitiveness. At the same time, the company actively lays out new forms of molecular biology such as peptide drugs
Jiuzhou Pharmaceutical (603456.SH): cumulative share repurchases of 3.895,300 shares
Gelonghui, May 6, 丨 Jiuzhou Pharmaceutical (603456.SH) announced that as of April 30, 2024, the company had repurchased a total of 3,895,300 shares through centralized bidding transactions. The repurchased shares accounted for 0.43% of the company's total share capital. The highest transaction price was 22.18 yuan/share, the lowest price was 15.11 yuan/share, and the total amount paid was 69,993,558.10 yuan (excluding transaction fees).
Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Profits May Not Reveal Underlying Issues
The market for Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) stock was strong after it released a healthy earnings report last week. However, we think that shareholders should be cautious
Jiuzhou Pharmaceutical (603456.SH) reported first-quarter results, net profit of 237 million yuan, a year-on-year decrease of 15.65%
Jiuzhou Pharmaceutical (603456.SH) released its report for the first quarter of 2024. The company achieved operating revenue during the reporting period...
Jiuzhou Pharmaceutical (603456.SH): Japanese CRO mainly focuses on innovative drug CMC business
Gelonghui, April 16 | Jiuzhou Pharmaceutical (603456.SH) said on the investor interactive platform that Japan's CRO company mainly focuses on innovative drug CMC business and is expected to be put into use in the third quarter of 2024.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Analysts Just Slashed This Year's Estimates
The analysts covering Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for thi
Jiuzhou Pharmaceutical (603456.SH): Net profit increased 12.17% year-on-year in 2023, and plans to pay 10 to 5 yuan
Gelonghui, April 8, 丨 Jiuzhou Pharmaceutical (603456.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 5,523 billion yuan, an increase of 1.44%; net profit attributable to shareholders of listed companies was 1,033 billion yuan, up 12.17% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1,024 million yuan, up 10.46% year on year; and basic earnings per share. It is proposed to distribute a cash dividend of 5.00 yuan (tax included) for every 10 shares to all shareholders.
Jiuzhou Pharmaceutical Gets Nod to Market Sitagliptin Metformin Tablets; Shares Drop 4%
Zhejiang Jiuzhou Biopharmaceutical, a unit of Zhejiang Jiuzhou Pharmaceutical (SHA:603456), obtained a drug registration certificate from China's National Medical Products Administration for its sitag
Jiuzhou Pharmaceutical (603456.SH) received the drug registration certificate for sitagliptin metformin tablets (II)
Jiuzhou Pharmaceutical (603456.SH) issued an announcement. Zhejiang Jiuzhou Biomedical Co., Ltd., a holding subsidiary of the company, received...
Jiuzhou Pharmaceutical (603456.SH): A total of 2.0252 million shares were purchased at a cost of 39.981 million yuan
Gelonghui, April 1, 丨 Jiuzhou Pharmaceutical (603456.SH) announced that as of March 31, 2024, the company had repurchased 2,052 million shares through centralized bidding transactions. The repurchased shares accounted for 0.23% of the company's total share capital. The highest transaction price was 22.18 yuan/share, the lowest price was 16.33 yuan/share, and the total amount paid was 39.981 million yuan (excluding transaction fees).
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
With its stock down 22% over the past three months, it is easy to disregard Zhejiang Jiuzhou Pharmaceutical (SHSE:603456). However, stock prices are usually driven by a company's financial performan
Does Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like
Jiuzhou Pharmaceutical (603456.SH): A total cost of 274.58 million yuan to buy back 0.1527% of the shares
Gelonghui, March 1, 丨 Jiuzhou Pharmaceutical (603456.SH) announced that as of February 29, 2024, the company had repurchased a total of 1,373,700 shares through centralized bidding transactions. The repurchased shares accounted for 0.1527% of the company's total share capital. The highest transaction price was 22.18 yuan/share, the lowest price was 16.33 yuan/share, and the total amount paid was 27,458,243 yuan.
Those Who Invested in Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Five Years Ago Are up 174%
Some Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) shareholders are probably rather concerned to see the share price fall 31% over the last three months. But that doesn't change the fact t
Lacklustre Performance Is Driving Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) 26% Price Drop
Unfortunately for some shareholders, the Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) share price has dived 26% in the last thirty days, prolonging recent pain. The recent drop completes
Minsheng Securities: The policy favors the transfer of overseas drugs to domestic production, optimistic about domestic CDMO leaders
The transfer of drugs produced overseas to domestic production ushered in favorable policies, and China's high-quality production capacity is expected to accelerate its entry into the supply chain of overseas pharmaceutical companies.
Jiuzhou Pharma to Build $42 Million CRO Platform in Japan
Jiuzhou Pharmaceutical (SHA:603456) plans to establish a unit in Japan to build a contract research organization (CRO) platform with a total investment of about $42 million. The move is in line with t
Jiuzhou Pharmaceutical (603456.SH): Some directors and supervisors plan to increase their shares by a total of 15 million yuan to 20 million yuan
Gelonghui, January 23, 丨 Jiuzhou Pharmaceutical (603456.SH) announced that some directors and senior management of the company plan to increase their A-shares through centralized bidding within 6 months from January 24, 2024 through the Shanghai Stock Exchange trading system. The total amount of increase in holdings will not be less than RMB 15 million, and not higher than RMB 20 million. There is no fixed price or price range for this increase in holdings.
Jiuzhou Pharmaceutical (603456.SH): Plans to establish a wholly-owned subsidiary in Japan to invest about 42 million US dollars to build a CRO service platform
Gelonghui, January 22丨Jiuzhou Pharmaceutical (603456.SH) announced that the company held the 3rd meeting of the 8th board of directors on January 22, 2024 to review and pass the “Proposal on Establishing a Wholly-Owned Company to Invest and Build a CRO Service Platform in Japan”, agreeing that the company plans to use its own funds to adopt Raybow Life Sciences (Singapore) PTE, a wholly-owned subsidiary of the company in Singapore. LTD. Set up a wholly-owned subsidiary in Japan to build a CRO service platform. The total investment of the project is expected
Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Last Week's 3.8% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
Key Insights The considerable ownership by private companies in Zhejiang Jiuzhou Pharmaceutical indicates that they collectively have a greater say in management and business strategy 51% of the bus
Analysis
Price Target
No Data
